by Grow Up Conference | Jun 24, 2024 | Cannabis News Wire, Media Partners
CannaCon Midwest St. Paul invites like-minded entrepreneurs, investors, public officials, patients, and enthusiasts of the cannabis spectrum, to attend the CannaCon Midwest St. Paul conference August 16-17, 2024. This event is a one-stop solution for the cannabis community looking for resources, education, and collaboration opportunities, for all things cannabis.
The CannaCon conference offers a phenomenal platform for enthusiasts, creatives, growers, and traders in and around the venue, to stay updated with the latest industry trends and develop the best networking connections. They will find the latest cultivation techniques, genetics, supplies, unique industry innovations, business, financial, and legal advice, marketing, branding and more, all under one roof.
World-class leaders and veterans of the cannabis trade will grace the event with their presence. Exhibitors will set up booths at the expo showcasing their latest offerings and innovative ideas. Investors looking for new investment opportunities will find a plethora of potential leads on the exhibitor floor. The event offers one-to-one meetings among entrepreneurs, executives, and investors for an in-depth understanding of the goals and vision of both parties.
Apart from the expo, the event will showcase speaker sessions and panel discussions featuring Former Governor and pro wrestler Jesse Ventura. He will interact with the audience, answer their queries, and offer insightful tips. CannaCon is a global networking forum where cannabis businesses and investors connect to discover new talent and develop long-term collaborations. This event promises greater trade and opportunities for cannabis industries in the region.
New as well as seasoned entrepreneurs pitch their businesses at their exhibitor booths to avail the enormous reach and connections that the CannaCon conferences offer. The event organizers ensure exhibitors have all the requisite resources at their disposal for setting up their booths.
To learn more, please visit https://cnw.fm/gyZu0
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Jun 24, 2024 | Cannabis News Wire, Media Partners
- Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2
- The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration
- The study’s main objective is to evaluate Lexaria’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug, semaglutide, currently commercially available as Rybelsus(R)
- The commencement of the pilot study shows Lexaria’s commitment to its promise to focus on GLP-1 studies for 2024, along with its confidence in its DehydraTECH technology
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study aims to evaluate the company’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1) drug semaglutide, which is currently commercially available in the branded product Rybelsus(R) (https://cnw.fm/tQM4o).
This second round of dosing utilized Rybelsus processed with DehydraTECH and is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database (“FDA IID”), which was administered with swallowed capsules. All nine study participants were successfully dosed, building on the initial study arm, which used a positive control Rybelsus swallowed tablet, whereas the third arm will explore an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.
This third and final study arm will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can be absorbed into the bloodstream at any level systemically into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed pill administration. This study is set to be completed in early July. If successful, this study will help remedy the downsides of swallowed administration, which is heavily impacted by the stomach’s acidic environment. This environment significantly degrades GLP-1 drugs swallowed, resulting in meager blood absorption rates of less than 1% when absorption technology is not used.
This move aligns with Lexaria’s plan to focus on GLP-1 studies for the 2024 calendar year. It also speaks to its commitment and overall confidence in the potential of its DehydraTECH technology. It is an important milestone for the company, mainly since, at the very beginning, the GLP-1 studies were considered a “high-risk” program, according to its CEO, Chris Bunka. This was mainly attributed to the fact that the study fell under a class of drugs considered “large molecules,” a class that the company had never explored before, especially given its focus on “small molecules” (https://cnw.fm/XYRTU).
So far, Lexaria has achieved great success with its GLP-1 studies. In addition, the rising interest in GLP-1 drugs, owing to their health benefits, has seen the company double down on this research going forward. The successful completion of the second round of dosing for its GLP-H24-2 human pilot study indicates this commitment while ushering in what’s to come for the company.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Jun 24, 2024 | Extraction Magazine, Media Partners
In recent years, the legalization of cannabis has become a topic of discussion almost all over the world. This is a very divisive topic and in different parts of the world it can be addressed in various ways. Cannabis legalization isn’t just about recreational use. From medical research, we have discovered how cannabidiol (CBD), the non-psychotropic active ingredient of cannabis, can bring improvements to people with anxiety disorders and insomnia problems, but also in the treatment of chronic pain or to relieve the symptoms of Parkinson’s disease. [1]
In addition to the medical aspect, there are other important factors to take into consideration. The legalization of cannabis affects several aspects of our society, including public health and safety, social justice, and even the economy. Legalization would increase the revenue of a state that regulates its sale, creates jobs, and attracts tourists, as already happens in states where cannabis is legal. By legalizing cannabis, distribution can be controlled and regulated, consequently reducing crimes related to illegal dealing. Addiction would no longer be seen as the consequence of a criminal attitude, but as a pathology to be treated.
The debate on the legalization of cannabis is a topic that is treated in completely opposite ways in different regions of Europe. The laws in this regard can vary slightly or greatly from one state to another and only this data can help us to understand how a culture can have different thoughts and attitudes towards a delicate topic like this one.
The Debate on Legality
The legalization of cannabis, as already mentioned, does not only concern recreational use but also impacts very important aspects of society. When we talk about legalization, we enter into a range of political and social nuances. Mainly, when talking about legalization, the following concepts are taken into consideration.
- Medical use: numerous studies have now shown how CBD can alleviate the symptoms of serious diseases. From mild insomnia to chronic pain therapy, it is now scientifically proven that cannabis, if prescribed by a doctor and used diligently, can potentially help people in different health conditions.
- Decriminalization: the reduction of penalties for those found in possession of small quantities of cannabis or derivatives. So that we can treat consumers as consumers, not as criminals. Watch out! Decriminalization does not mean legalization, but only a reduction of the sentence, which can go from a criminal offense to a simple administrative sanction.
- Legalization: involves a more profound change in how the state manages and regulates the phenomenon of cannabis consumption. The doors would be opened to a market controlled and managed by the state, which legitimately recognizes its production, consumption, and sale, all regulated by clear and transparent laws.
These are the main aspects to take into consideration to better understand how to approach the debate on the legalization of cannabis. Each nation in Europe approaches the issue differently, reflecting different cultures, customs, political priorities, and social concerns. Obviously, the issue is more complex than that, standardizing the use of cannabis requires many legislative processes. The real challenge is balancing control and minimizing the risk to consumers in order to maximize the potential benefits.
An Overview of Cannabis in Europe
The cannabis situation in Europe is varied. Some countries have made considerable progress in this regard, while others remain on a more conservative stance.
Malta
The recreational use of cannabis is already approved. Maltese laws allow the consumer to grow his own plant at home for personal consumption. Associations can also be created where members can grow and consume cannabis. Malta is a great example of how legalization can be applied in the European context.
Luxembourg
Luxembourg is also following the same line, the details to this date are still to be defined, but the objective is to reduce the black market and provide safe and controlled access to cannabis.
Germany
The government is implementing plans for legalization. In doing so, Germany is trying to create a legal market to completely eliminate drug dealing and better protect consumers. The German government aims to legalize the sale and possession of cannabis for personal use, paying particular attention to the production aspect.
These are three virtuous examples of how a solution can be found that is positive for both the state and the consumer. These are the symptoms of the beginning of a change that could spread throughout Europe. These are notable steps forward if we consider that until a few years ago, cannabis was seen exclusively as a problem to be eliminated that caused crime.
In recent years, however, from a regulatory point of view, few steps have been taken on the path towards legalization. But some models of legalization and regulation have arisen in several states of the American continent, such as Uruguay, California, and Canada, which are starting to influence some European states, such as the countries mentioned above.
Switzerland
In Switzerland for example, the consumption of any narcotic substance is considered a crime, only the sale of cannabis with low tetrahydrocannabinol (THC) contents is permitted.
Denmark
With up to 50 grams of inflorescences or 10 grams of cannabis resin, there is a presumption of possession for personal consumption. This detention for personal use may be subject to a simple warning or a fine of around 70 euros.
Portugal
In Portugal, the situation is very interesting. Below the tolerated quantity of possession (25 grams of inflorescences and 5 grams of cannabis resin), consumption and possession are considered administrative offenses. If found in possession of a quantity that does not exceed the legal limit, the user will have to appear before a commission for the dissuasion of drug addiction. With three interviews the commission must evaluate whether the user is in a problematic situation or not. The commission can suspend the proceedings if the risk of recurrence is minimal, if the risk is moderate, it offers the user psychological support, if the risk is high, the consumer is sent to a specialized assistance center, and if he refuses treatment, he risks a fine of 25 to 150 euros.
Spain
The 2015 law on civil security classifies the consumption and possession of drugs (including cannabis) in public places as a serious administrative infraction, punishable by a fine ranging from 601 to 30,000 euros, while the consumption and use for the purposes of personal consumption in private places are not considered crimes. In Malta, a similar distinction is made: the use of cannabis is permitted from the age of 18, but it is strictly prohibited in public places as well as in any private place where minors are present. Infringement of these laws entails fines that range from 300 to 500 euros.
England
In England, the police apply progressive sanctions if found in possession of a small quantity of cannabis. In the case of a first offense, the police can dismiss the whole thing with a simple warning. In the event of a repeat offense, however, you may incur a fine of up to 100 pounds. The interesting and unusual aspect is that there is no minimum quantity decided by law, the minimum quantity allowed is at the discretion of the police.
The Netherlands
In the Netherlands, the directives of the Attorney General are very clear. If found in possession of 5 grams or less of cannabis, the case is dismissed, between 6 and 30 grams, you incur a fine ranging from 75 to 100 euros in the event of a repeat offense, from 30 grams onwards, you incur prison sentences. The production of cannabis in the Netherlands is considered a criminal offense, but in reality, since 1976, the sale has been tolerated in coffee shops, as long as the regulations called “tolerance criteria” of the Attorney General and the municipalities are respected.
– Commercial stock must not exceed 500 grams;
– No more than 5 grams can be sold per day to a single person;
– Coffee shops must not cause public nuisance;
– The sale of cannabis to minors is prohibited, and they cannot enter coffee shops;
– The sale of hard drugs and alcohol is prohibited;
– Advertising inside and outside coffee shops is prohibited.
The Dutch model, although it has worked for years, is based on rules that, at first glance, might seem contradictory. For example, distribution and sales are tolerated, but not production and distribution. [2]
Italy
In Italy, the history of cannabis is controversial. In the 1950s, Italy was the world’s second largest producer of industrial hemp, second only to the Soviet Union. Over one hundred thousand hectares of land, used mainly for textile purposes. Since the early 1900s, Italy has established itself as a protagonist in the cannabis cultivation market, seeing its peak in the 1950s and its decline immediately afterwards. In fact, in 1961, the UN single convention on narcotics was signed in New York, and from here began the era of prohibition, which spread like wildfire throughout the world.
Thus, in Italy, the legislation of the time downgraded hemp as an economic resource to a plant of transgression, also thanks to industrial development and the invention of synthetic materials.
Over the years in Italy, the law on the consumption and production of cannabis has made a circular journey to return to the starting point. At the beginning of the 1990s, the Iervolino-Vassalli law differentiated hard drugs from soft drugs, personal consumption and dealing and production were considered illicit, but the differences between the two categories of drugs were taken into consideration. For consumption, the sanctions were mainly administrative, and only recidivism or massive production and distribution led to imprisonment.
In 2006, however, there was an important modification, with the Fini-Giovanardi law, which no longer distinguished between light and heavy substances nor personal use from illegal dealing. This law also ignored the scientific evidence that proves the differences between hard and soft drugs, generalizing everything to try to provide a solution to the fight against drugs without realizing that these measures did more harm than good. The consumer was treated like a criminal, the drug addict was branded for life as a person to be imprisoned and not helped. A boy caught smoking a joint was treated like a serial drug dealer, moving large quantities of hard drugs illegally.
After eight years, the Italian Constitutional Court decreed this anti-constitutional law, thus, we returned to the Iervolino-Vassalli law, which is still in force, a step backwards that, in reality, could seem like a step forward towards understanding and legalizing cannabis. (3)
Conclusions
Unfortunately, the list of European countries where cannabis is completely illegal is long. Nevertheless, in many of these places, the law is moving to allow the use of CBD-containing cannabis for medical purposes, and this is a very important first step in order to start a journey of understanding and studying a plant that in recent decades has been seen only as harmful, when from an economic, industrial and medical point of view, it can bring many benefits to people who know how to use it.
References:
[1] Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179. Epub 2014 May 21. PMID: 24845114.[2] https://www.senat.fr/lc/lc306/lc306.html#toc27
[3]https://books.google.it/books?id=FYqADQAAQBAJ&lpg=PT5&ots=uqTXhBBGpO&dq=la%20legalizzazione%20della%20cannabis%20in%20italia&lr&hl=it&pg=PT12#v=onepage&q&f=false
by Grow Up Conference | Jun 24, 2024 | Grow Opportunity, Media Partners
By The Washington Post Editorial Board
Maryland’s legalization of recreational marijuana just over a year ago has obviously been a boon to users. But it has also benefited the state, bringing in more than $26 million in tax revenue during the second half of 2023. Meanwhile, citizens with possession convictions on their records, most of whom committed crimes that wouldn’t be punished at all anymore, were left behind. Last week, Gov. Wes Moore (D) did the right thing and pardoned them.
Read the full story here.
by Grow Up Conference | Jun 24, 2024 | Cannabis Prospect Magazine, Media Partners
The Global Medical Cannabis Market Size is to Grow from USD 17.60 Billion in 2023 to USD 121.33 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 21.30% during the projected period.
Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4591
Medical cannabis is an herbal medication derived from cannabis plants that is used to treat a specific symptom or ailment. Cannabis includes a number of active chemicals, including THC (tetrahydrocannabinol) and CBD (cannabidiol), which have been shown to have potential therapeutic benefits. These qualities might include pain alleviation, inflammation reduction, anti-nausea effects, muscle relaxation, and hunger enhancement, among others.
Medical cannabis is used to treat symptoms of chronic pain, epilepsy, multiple sclerosis, chemotherapy-induced nausea, and some mental health issues like anxiety and PTSD. It can be administered by numerous techniques, such as smoking, vaporization, oils, tinctures, capsules, foods, and topical applications. The worldwide medical cannabis market is expanding rapidly due to a number of factors. The increasing legalization of medical cannabis in numerous nations and states opens up chances for market expansion, allowing businesses to enter and operate legally.
Furthermore, cannabis is becoming more widely accepted as a genuine type of treatment, resulting in a shift in perspective and greater demand for medical cannabis products. Patients and healthcare providers are becoming more aware of the health benefits of cannabis, particularly in managing chronic diseases, which is increasing demand. However, the global medical cannabis market has a number of barriers that prevent universal acceptability and accessibility. Legal restraints and complex regulatory systems in many areas impede its production, distribution, and prescription.
Browse key industry insights spread across 220 pages with 110 Market data tables and figures & charts from the report on the “Global Medical Cannabis Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Flower, Concentrates, Edible, Others), By Application (Chronic Pain, Arthritis, Migraine, Cancer, Diabetes, AIDS, Epilepsy, Parkinson’s Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.”
Buy Now Full Report: https://www.sphericalinsights.com/checkout/4591
The concentrates segment is anticipated to hold the greatest share of the global medical cannabis market during the projected timeframe.
Based on the product type, the global medical cannabis market is classified into flower, concentrates, edible, and others. Among these, the concentrates segment is anticipated to hold the greatest share of the global medical cannabis market during the projected timeframe. Concentrates provide a strong and convenient way to take cannabis for medical purposes, with increased doses of cannabinoids such as THC or CBD. They can be ingested in a variety of ways, including vaping and dabbing, giving patients a variety of alternatives for controlling medical issues.
The chronic pain segment is anticipated to grow at the fastest pace in the global medical cannabis market during the projected timeframe.
Based on the application, the global medical cannabis market is divided into chronic pain, arthritis, migraine, cancer, diabetes, aids, epilepsy, and Parkinson’s disease. Among these, the chronic pain segment is anticipated to grow at the fastest pace in the global medical cannabis market during the projected timeframe. This development can be ascribed to the broad incidence of chronic pain globally, the limitations of conventional treatments, and the growing acceptance and legality of medical cannabis.
The hospital pharmacies segment had the highest revenue share during the projection period.
Based on the distribution channel, the global medical cannabis market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment had the highest revenue share during the projection period. Hospital pharmacies are frequently outfitted with strong quality control systems and manned by qualified specialists who can ensure that medical cannabis is properly administered to patients. Furthermore, patients may feel more comfortable getting medical cannabis from a hospital setting because of the perceived legitimacy and expertise associated with these organizations.
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/4591
North America is expected to hold the largest share of the global medical cannabis market over the forecast period.
North America is expected to hold the largest share of the global medical cannabis market over the forecast period. This dominance is attributable to early legalization attempts in many states and provinces, substantial investments in research and production facilities, expanding regulatory frameworks and growing public acceptance of medical cannabis. With a well-established healthcare infrastructure and increased support from healthcare experts, North America remains a crucial hub for the medical cannabis sector, driving significant revenue and market expansion in the near future.
Asia Pacific is predicted to grow at the fastest pace in the global medical cannabis market during the projected timeframe. This expansion can be due to several factors such as increasing acceptance of medical cannabis, developing legal frameworks, raising awareness about the potential therapeutic advantages of cannabis, and expanding research and development activities in the region. Furthermore, factors such as the vast population base and increased frequency of chronic conditions lead to demand for medical cannabis products, fueling market expansion in the Asia Pacific region.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major key players in the global medical cannabis market include Aurora Cannabis Inc., MedReleaf Corp., TerrAscend Corp, Canopy Growth Corporation, GW Pharmaceuticals, Akumentis Healthcare Ltd., Hexo Corp., Insys Therapeutics Inc., Medical Marijuana Inc., Cardiol Therapeutics, Harvest Health & Recreation, Inc., CannTrust Holdings Inc., Aphria Inc., and Others.
Get Discount At @ https://www.sphericalinsights.com/request-discount/4591
Recent Developments
In March 2023, Irwin Naturals Inc., known for its high-quality vitamins, supplements, and CBD products, launched CBD 25mg Softgels in Canada. These soft gels are now available countrywide via the Starseed Medical Medical Group portal. Irwin Naturals Cannabis plans to market the first of five CBD and THC products across Canada in the coming months as part of a licensing arrangement with Entourage Health Corp.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global medical cannabis market based on the below-mentioned segments:
Global Medical Cannabis Market, By Product Type
- Flower
- Concentrates
- Edible
- Others
Global Medical Cannabis Market, By Application
- Chronic Pain
- Arthritis
- Migraine
- Cancer
- Diabetes
- AIDS
- Epilepsy
- Parkinson’s Disease
Global Medical Cannabis Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Howitzer Systems Market, Regional Analysis
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
Browse Related Reports
Global Nucleotides Market Size, Share, and COVID-19 Impact Analysis, By Nitrogenous Base (Purine and Pyrimidine), By Application (Diagnostics Research, Pharmaceuticals, and Others), By Technology (TaqMan Allelic Discrimination and SNP By Pyrosequencing), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033
Global Empty Capsules Market Size, Share, and COVID-19 Impact Analysis, By Type (Gelatin and Non-Gelatin), By Functionality (Immediate-Release, Sustained-Release, Delayed Release, and Others), By Therapeutic Application (Vitamin & Dietary Supplements, Antibiotic & Antibacterial Drugs, Cardiac Therapy Drugs, Antacids & Anti-flatulent preparations, and Others), By End User (Pharmaceutical, Nutraceutical, Cosmetic, Reference Laboratories, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033
Global Multiplex Assay Market Size, Share, and COVID-19 Impact Analysis, By Type (Protein Based Multiplex Assays, Nucleic Acid-Based Multiplex Assay, and Other Multiplex Assays), By Product (Consumables and Software), By Technology (Flow Cytometry, Fluorescence Detection, Luminescenc, Multiplex Real-time PCR, & Other Technologies), By Application (R&D and Clinical Diagnostics), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032.
Global Ambulance Equipment Market Size, Share, and COVID-19 Impact Analysis, By Equipment Type (Transportation, Burn Care, Diagnostic and Infection Control, Blood and Hemorrhage Control, Respiratory, Hypothermia, Cardiac, and Other Equipment), By End-User (Air Ambulance, Water Ambulance, and Ground Ambulance), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company’s mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter
by Grow Up Conference | Jun 24, 2024 | Grow Opportunity, Media Partners
(CNW) Vancouver — StickIt Technologies Inc., an Israeli technology and cannabinoid company, announces today reorganization and reduction of significant expenses.
As part of the reorganization, the company intends to reduce significant expenses in its activities around the world. The company decided in January 2024 to close the raw materials factory in Galilee, Israel, due to the war and move the raw materials production activity to Calgary, Canada.
During the end of the 3rd quarter of 2024, the company intends to close its subsidiary StickIt Thailand Ltd (based in Thailand) in accordance with the government’s statement on ending the recreational use of cannabis in the country. The company also intends to close StickIt Spain’s CBD manufactory and the company’s offices in Barcelona and transfer the producing franchise to a local distributor.
“The world’s cannabis industry is facing many challenges – which affects most companies in the industry and probably affects the share value. It is necessary to reduce costs and try to increase our technology sales worldwide. These actions will save the company about $120,000 CAD a year,” concluded Eli Ben Haroosh, CEO of StickIt Technologies Inc.
The CEO went on to say that during Q3 2024, StickIt’s Research Unit will produce the special THC straw for mass creation.
by Grow Up Conference | Jun 24, 2024 | Grow Opportunity, Media Partners
US President Joe Biden’s plan to downgrade marijuana, whether politically motivated or empathic, is a regressive step in the global fight against drugs, say Tan Chong Huat and Narayanan Ganapathy from Singapore’s National Council Against Drug Abuse
June 24, 2024 By Channel News Asia
SINGAPORE – The United States has formally moved to loosen restrictions on marijuana, with plans to reclassify it as a less harmful drug.
Under the move, marijuana – which has been classified since 1970 as a Schedule I drug alongside heroin, LSD and ecstasy – will be downgraded to a Schedule III drug, putting it in the same category as drugs like testosterone or painkillers containing codeine. Schedule III drugs are deemed to have a “moderate to low potential” of dependence.
Read the full story here.
by Grow Up Conference | Jun 24, 2024 | Cannabis Prospect Magazine, Media Partners
Metasphere Labs Inc. announced the signing of a definitive Software Development Agreement dated June 21, 2024 (the “Agreement”) with ARCannabis BC Ltd., a prominent cannabis retailer based in British Columbia. This partnership aims to enhance the online cannabis shopping experience with the use of advanced virtual reality (VR) technology.
Pursuant to the Agreement, Metasphere Labs will design, develop, and deliver a state-of-the-art VR virtual store for AR Cannabis, leveraging either ThreeJS or Unreal Engine to create an immersive 3D user interface. The virtual store will be accessible on Google Chrome, Safari, and Microsoft Edge browsers, providing a seamless and engaging shopping experience for customers.
The new VR virtual store will integrate with ARCannabis’ existing backend shopping cart system, powered by the Cova software service platform, ensuring a smooth transition and enhanced functionality. Customers will enjoy the same features as the current online store, with the added benefit of a fully immersive virtual shopping environment. Additionally, the store is being designed to be embeddable in open metaverse environments and gaming platforms like Fortnite, subject to their terms of service, broadening its accessibility and appeal.
“We are thrilled to partner with ARCannabis to bring their vision of a VR virtual store to life,” said Natasha Ingram, CEO of Metasphere Labs. “Our expertise in developing immersive metaverse environments aligns perfectly with AR Cannabis’ innovative approach to retail. This collaboration will set a new standard for the online shopping experience in the cannabis industry.”
The development of the VR virtual store is set to be completed by September 1, 2024, followed by a 30-day testing period to ensure it meets all agreed specifications and functionalities. The project is valued at $8,000, reflecting Metasphere Labs’ commitment to delivering high-quality, innovative solutions within a competitive budget.
“We are excited to work with Metasphere Labs to enhance our customers’ shopping experience,” said Joe Le, Co-Founder of ARCannabis. “This VR virtual store will not only showcase our products in a unique and engaging way but also reinforce our commitment to leveraging technology to improve customer satisfaction.”
This Agreement further solidifies Metasphere Labs’ position as a leader in the development of immersive and interactive virtual environments. The Company’s dedication to innovation and excellence continues to drive its success in the rapidly evolving Web3 and metaverse industries. For more information about ARCannabis and their products, please visit https://arcannabis.ca/about-us/
About Metasphere Labs
Based in Vancouver, British Columbia, Metasphere Labs develops solutions for the metaverse, DAOs, gamification, and Web3, addressing social challenges related to climate change and aiming for a positive planetary impact. For more information, contact Natasha Ingram, CEO, at info@metasphere.earth.
About ARCannabis
ARCannabis is a Vancouver legal cannabis store chain, providing British Columbians with the highest quality recreational cannabis on the market.
by Grow Up Conference | Jun 24, 2024 | Cannabis Prospect Magazine, Media Partners
TeaPot, the cannabis-infused iced tea brand from The Boston Beer Company, announces two new expansions of its popular product lineup with the debut of Lemonade Iced Tea and CBD Lemon Black Tea.
CBD Lemon Black Tea
TeaPot’s first hemp-derived beverage contains 20mg of CBD and less than 0.5mg of THC. As demand for hemp-derived products grows, TeaPot meets the evolving needs of consumers with a thirst-quenching beverage that provides both great taste and a consistent cannabis experience. This 100-calorie, non-carbonated iced tea is currently available in dispensaries across Ontario and Quebec with plans for further expansion.
Lemonade Iced Tea
TeaPot’s Lemonade Iced Tea is a classic half-and-half recipe, combining real black tea with lemonade, expertly infused with 5mg of THC. Each 355mL can of Lemonade Iced Tea contains 130 calories and is non-carbonated. Available in dispensaries across Ontario and Quebec with further expansion planned throughout the year.
“TeaPot is thrilled to welcome two more options for your cooler,” said Paul Weaver, director and head of Cannabis at the Boston Beer Company. “TeaPot’s hemp-derived CBD Iced Tea is based on our award-winning THC recipe and might just be the best tasting CBD drink in the category. Our Lemonade Iced Tea is packed with flavour, contains 5mg of THC, and is the perfect summer refreshment.”
TeaPot iced teas are produced at Peak Processing Solutions (Windsor, Ontario) and available in dispensaries across Canada or online via the Ontario Cannabis Store. For more information, visit http://www.drinkteapot.com/ or follow @DrinkTeaPot on Instagram to receive the latest updates.
About The Boston Beer Company
The Boston Beer Company, Inc. began in 1984 brewing Samuel Adams beer and has since grown to become one of the largest and most respected craft brewers in the United States. We consistently offer the highest-quality products to our drinkers, and we apply what we’ve learned from making great-tasting craft beer to making great-tasting and innovative “beyond beer” products. Boston Beer Company has pioneered not only craft beer but also hard cider, hard seltzer, and hard tea. For more information, please visit our website at www.bostonbeer.com, which includes links to our respective brand websites.
by Grow Up Conference | Jun 24, 2024 | Cannabis Prospect Magazine, Media Partners
StickIt Technologies Inc., an Israeli technology and cannabinoid company, announces today reorganization and reduction of significant expenses.
As part of the reorganization, the company intends to reduce significant expenses in its activities around the world. The company decided in January 2024 to close the raw materials factory in Galilee, Israel, due to the war and move the raw materials production activity to Calgary, Canada. During the end of the 3rd quarter of 2024, the company intends to close its subsidiary StickIt Thailand Ltd (based in Thailand) in accordance with the government’s statement on ending the recreational use of cannabis in the country. The company also intends to close StickIt Spain’s CBD manufactory and the company’s offices in Barcelona and transfer the producing franchise to a local distributor.
“The world’s cannabis industry is facing many challenges – which affects most companies in the industry and probably affects the share value. It is necessary to reduce costs and try to increase our technology sales worldwide. These actions will save the company about $120,000 CAD a year,” concluded Eli Ben Haroosh, CEO of StickIt Technologies Inc.
The CEO went on to say that during Q3 2024, StickIt’s Research Unit will produce the special THC straw for mass creation.
About StickIt Technologies Inc
StickIt is a technology company that invented and manufactures innovative products (“devices”) that can contain varying quantities of CBD/THC for recreational and medical cannabis users. Its operating model is to establish joint ventures/licensees (“partners”) in countries around the world that will establish a production facility in which they will add the cannabinoid content to the “sticks” and “straws” produced and supplied by StickIt. The Company’s precise dosing options cater to a wide range of effects, including painkilling, energizing, focus, sleep improvement, etc., and can be tailored to meet local preferences and regulations. StickIt Technologies serves customers worldwide.
About Ripco Processing Inc.
Ripco, known for its innovative cannabis products, brings popular brands like StickIt and StripIt to the Canadian market. StickIt is an infused stick designed to enhance the performance of prerolls, promising to take user experiences to new levels – just StickIt!
Recent Comments